SHANDONG XINHUA (00719) rose more than 7% in the afternoon session. At the time of writing, the stock was up 6.76% to HK$6.63, with a turnover of HK$23.13 million.

The catalyst for the move was news that the company's self-developed Benserazide Hydrochloride active pharmaceutical ingredient (API) has officially received the "Chemical API Marketing Authorization Approval Notice" issued by the National Medical Products Administration, permitting its commercial production and sale.

This marks another significant achievement for Shandong Xinhua in the field of neurological disease treatment and represents a new breakthrough in the company's comprehensive drug supply chain for Parkinson's disease.

Benserazide Hydrochloride is a peripheral dopa decarboxylase inhibitor. As a core component of the classic Parkinson's disease treatment compound "Levodopa/Benserazide," it can significantly reduce the peripheral adverse effects of Levodopa and enhance therapeutic efficacy.

The finished dosage form containing this API is classified as a Category A drug in the "National Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance Drug List (2025)."

According to relevant statistical data, sales of Benserazide-related preparations in China's public medical institutions in 2025 were approximately RMB 1.4 billion.